However, clinical trials targeting VEGFA in gliomas have not achieved the anticipated goals, as the administration of bevacizumab, an anti-VEGFA drug approved by the FDA for recurrent GB, has shown limited survival benefit30. The gene discussed is VEGFA; the disease is central nervous system cancer.